More understanding about the biological behavior and intrinsic subtypes of gastric cancer has been explored through PDX models, especially the human epidermal growth factor receptor-2 (HER2)-amplified subtype of gastric cancer confirmed HER2 as the first validated therapeutic target for esophageal cancer. This evidence concerns the gene ERBB2 and gastric cancer.